Core Viewpoint - The company, Te Yi Pharmaceutical (002728), has shown a positive stock performance with a closing price of 11.29 yuan, reflecting a 2.73% increase on November 3, 2025, alongside significant trading activity [1]. Trading Information Summary - On November 3, 2025, the net inflow of main funds into Te Yi Pharmaceutical was 19.40 million yuan, accounting for 1.76% of the total transaction amount [2][5]. - Retail investors experienced a net outflow of 21.23 million yuan, representing 1.93% of the total transaction amount [2]. Stock Performance and Market Activity - Te Yi Pharmaceutical was listed on the "Dragon and Tiger List" due to its daily turnover rate reaching 20%, marking the second time it has appeared on this list within the last five trading days [3][5]. Company Developments - The company has established a solid operational foundation in Hainan with its wholly-owned subsidiaries, Hai Li Pharmaceutical and Hai Li Doctor Pharmaceutical, which are registered in Haikou, Hainan [4]. - The Hainan Free Trade Port has introduced a series of supportive policies for the biopharmaceutical industry, covering all aspects from research and development to production and industrial upgrading, creating a favorable environment for pharmaceutical companies [4]. - The company is actively researching and aligning with these policies to leverage opportunities and integrate policy benefits with its existing business and future plans [4].